News: Amarin Corporation PLC (AMRN.O)
12 Dec 2013
Fri, Nov 22 2013
- Amarin Corp Plc said the Food and Drug Administration did not accept its appeal for the review of a regulatory decision to revoke an agreement related to the trial of its lead drug that lowers a type of blood fat.
Nov 22 - Amarin Corp Plc said the U.S. Food and Drug Administration did not accept its appeal for the review of a regulatory decision to revoke an agreement related to the trial of its lead drug that lowers a type of blood fat.
- Amarin Corp Plc's shares slumped as much as 64 percent on Thursday, a day after an advisory committee to the U.S. Food and Drug Administration voted against allowing the company's triglyceride-lowering drug for use in a broader patient population.
- Amarin Corporation Plc's triglyceride-lowering drug Vascepa should not be approved for use in a broader patient population until results from an additional study have been analyzed, an advisory panel to the U.S. Food and Drug Administration said on Wednesday.
- Shares of Amarin Corporation Plc fell 20 percent on Friday on concerns the U.S. Food and Drug Administration will reject its application to market Vascepa, a drug that lowers blood fat levels, to a broader patient population.
- Your Vote Counts: Who is the Worst Biotech CEO of 2013?
- Acasti Pharma: 7 Different Insiders Have Purchased Shares This Month
- Will Amarin And Arena See Better Sales In 2014?
- 4 Biotech Stocks Under $10 to Watch
- Amarin Dangles A Carrot On A Mile Long String
- Amarin in Deep Hole so Top Execs Get Cash Bonus Offer
- Proposed Offering and Amendments, Patents, Results, and Announcements by Healthcare Companies - Research Report on Forest Laboratories, OncoMed, EnteroMedics, Cadence, and Amarin
- Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
- Amarin Announces Notification of Patent Allowances for U.S. Applications 13/685,281, and 13/685,291 Related to Triglyceride Lowering With a Mixture of Omega-3 Free Fatty Acid (Including EPA and/or DHA) in Both the MARINE and
- Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Amarin Corporation plc
- SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Amarin Corporation, plc and Certain Officers - AMRN
- Kantrowitz, Goldhamer & Graifman, P.C. Files Class Action Suit Against Amarin Corporation plc
- AAAResearchReports.com Pre-Market Technical Analysis: Elan Corp., Amarin Corp., Cubist Pharmaceuticals, and Seattle Genetics
- Bullish Stocks Commentary: Camtek Ltd, Lions Gate Entertainment, ImmunoCellular Therapeutics, Pandora Media, Amarin Corporation
- Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Amarin Corporation plc
- SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $150,000 in Losses from Investment in Amarin Corporation plc to Contact Brower Piven Before the January 3, 2014 Lead Plaintiff Deadline